ISV - Sector: Healthcare --- Industry: Biotechnology & Drugs

[fill_the_gap]

It seems that ISV may be positioned for sale.

Watch trading and volume the next day or so.

[fill_the_gap]

Report the summarizes much of what they said tonight...

http://www.mikehav.com/isv8aug07note.pdf

[setravis]

ALAMEDA, Calif., Sep 11, 2007 (BUSINESS WIRE) -- InSite Vision Incorporated (ISV, Trade), an ophthalmic therapeutics company, today announced that S. Kumar Chandrasekaran, Ph.D., President and Chief Executive Officer, will present an overview of the company at the ThinkEquity Partners' Fifth Annual Growth Conference, Wednesday, September 19, 2007 at 8:30 a.m. Pacific Time in San Francisco, Calif.

The presentation will be webcast and may be accessed live on the investor relations section of the company's website at www.insitevision.com. The presentation will be available on this link for a limited time following the conference.

InSite Vision develops novel ophthalmic products including AzaSite(TM) (azithromycin ophthalmic solution) 1% for the treatment of bacterial conjunctivitis recently launched by Inspire Pharmaceuticals. Based on its proprietary DuraSite(R) topical sustained-release technology, InSite is expanding its portfolio of ophthalmic products to include AzaSite Plus(TM) and AzaSite Xtra(TM) with the potential to provide significant advantages currently not available with conventional treatment options. Additionally AzaSite Otic(TM) is under development for ear infections.

SOURCE: InSite Vision Incorporated


InSite Vision Incorporated 
Joyce Strand, 510-747-1220 

Copyright Business Wire 2007 ********************************************************************** As of Friday, 09-07-2007 23:59, the latest Comtex SmarTrend? Alert, an automated pattern recognition system, indicated an UPTREND on 08-07-2006 for ISV @ $1.73. For more information on SmarTrend, contact your market data provider or go to www.mysmartrend.com SmarTrend is a registered trademark of Comtex News Network, Inc. Copyright ? 2004-2007 Comtex News Network, Inc. All rights reserved.



Technicals
Close Above the 13-day MA
Percentage Gainer

Last Price Quote is:
2.79%above 13-day MA
-8.35%below 50-day MA
RS Rating: 9 

Fundamentals
Key Data:
Market Cap (M): $30.56 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 11/13/2007
Last Analyst Rating: Buy